CSL Of Australia Gets U.S. GMP Complaint Over Flu Vaccines
This article was originally published in PharmAsia News
Australia's CSL has received complaints by U.S. health authorities who question "objectionable conditions" under which the firm's new seasonal flu vaccine has been produced
You may also be interested in...
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.